INSOMNIA AND SOMNOLENCE INDUCED BY SECOND GENERATION ANTIDEPRESSANTS DURING THE TREATMENT OF MAJOR DEPRESSION: A Meta-Analysis

Alberti S.\textsuperscript{a,}\textsuperscript{c}, Serretti A.\textsuperscript{a,}\textsuperscript{d}, Andrisano C.\textsuperscript{a}, Chiesa A.\textsuperscript{a}\textsuperscript{b}

\textsuperscript{a} Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy
\textsuperscript{b} Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy
*Contact: siegfried.alberti@studio.unibo.it; alessandro.serretti@unibo.it

BACKGROUND
Insomnia and somnolence are side effects frequently associated with second-generation antidepressants and they have been found to reduce both quality of life and compliance with treatment [1]. Despite this evidence, relatively little attention has been given so far to define a clear rank of these side effects across different compounds.

THE AIM OF THE PRESENT META-ANALYSIS IS TO PROVIDE QUANTITATIVE DATA ABOUT SHORT-TERM RATES OF INSOMNIA AND SOMNOLENCE ASSOCIATED WITH COMMONLY EMPLOYED SECOND-GENERATION ANTIDEPRESSANTS DURING THE TREATMENT OF MAJOR DEPRESSION

METHODS
Literature research was conducted using MEDLINE, ISI Web of Science, the Cochrane database and references of retrieved articles. Unpublished documents were provided by pharmaceutical companies and Medical Control Agencies. Included studies had to: 1) focus on patients aged 18 or older; 2) suffering from Major depression (MD) according to the DSM-IV TR criteria; 3) investigate one or more of the above mentioned antidepressants; 4) provide dichotomous measures of drug-related insomnia and/or somnolence rates within the 12th week of treatment; 5) have a minimum duration of six weeks. According to these criteria, 276 studies could be included. Analysis. Eligible studies were entered in the Cochrane Collaboration Review Manager Software and analyzed by RevMan analysis 1.01. For studies that did not include a placebo control group, we calculated the weighted mean of the placebo samples for the considered variable from placebo-controlled studies that investigated the same variable and applied it to studies not including a placebo group [2]. Sensitivity analyses focused on: 1) double-blind, randomized placebo-controlled studies, 2) antidepressants mono-therapy studies; 3) non-sponsored studies.

RESULTS
Insomnia and somnolence rates in the short-term treatment of MD are shown in figure 1a and 1b. -within 12 weeks, high rates of insomnia were significantly associated to treatment with Bupropion and Desvenlafaxine - at the opposite, high rates of somnolence were associated to the treatment with Fluoxetine and Mirtazapine

By sensitivity analysis, slight influences on main findings were observed; however, the results of the general analysis were largely confirmed.

DISCUSSION
Different antidepressants are associated with different insomnia and somnolence rates; in particular, Bupropion, Desvenlafaxine, Agomelatine, Fluoxetine and Mirtazapine showed the most significant results. These findings are mainly related to their mechanisms of action. Treatment-related insomnia and/or somnolence are frequent adverse effects that should be considered in clinical practice to best tailor each antidepressant to the specific needs of each patient.

POTENTIAL CONFLICTS OF INTEREST: Dr. Serretti is or has been consultant/speaker for: Abbott, Angelini, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Pfizer, Sanofi, Servier. Dr. Chiesa is or has been consultant/speaker for: Abbott, Innovapharma. Dr. Andrisano and Dr. Alberti have no conflict to disclose.

This study was supported by Abbott Laboratories. The authors have no other relevant affiliations or financial involvement with any organization or entity in conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.

REFERENCES